Latigo Biotherapeutics LTGO
$13.00 −$0.24 (-1.81%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $13.00 0.00%
Open$13.22
Prev close$13.24
Day range$11.91 – $13.35
Volume267.2K
Market cap$861.89M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$22.93M+7.3% YoY
Net profit-$20.95M+15.5% YoY
Diluted EPS-$0.55+2.4% YoY
Free cash flow-$19.56M+1.8% YoY
Operating cash flow-$19.52M
Revenue, last 7 quarters
Net profit, last 7 quarters
Diluted EPS by quarter
Free cash flow by quarter
Profitability & balance sheet
Return on equity-27.2%
Return on assets-26.3%
Return on invested capital-28.1%
Current ratio29.11
Liabilities / assets3.5%
Cash & investments$401.24M
Total debt$483,000.00
Net cash (debt)$400.76M
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $408.46M | $64.76M | $50.58M | $75.52M | $75.52M |
| -Accounts Payable | $5.09M | $3.57M | $4.46M | $5.02M | $5.02M |
| Current Accrued Expenses | $4.67M | $8.78M | $8.63M | $8.67M | $8.67M |
| Short-Term Debt and Capital Lease Obligation | $705,000.00 | $30.60M | $502,000.00 | $563,000.00 | $563,000.00 |
| -Current Capital Lease Obligation | $705,000.00 | $705,000.00 | $502,000.00 | $563,000.00 | $563,000.00 |
| Total Non-Current Liabilities | $518,000.00 | $289.27M | $288.67M | $288.74M | $288.74M |
| Long Term Debt and Capital Lease Obligation | $483,000.00 | $648,000.00 | $52,000.00 | $127,000.00 | $127,000.00 |
| -Long Term Capital Lease Obligation | $483,000.00 | $648,000.00 | $52,000.00 | $127,000.00 | $127,000.00 |
| Convertible preferred securities | $0.00 | $288.58M | $288.58M | $288.58M | $288.58M |
| Other Non-Current Liabilities | $35,000.00 | $35,000.00 | $35,000.00 | $35,000.00 | $35,000.00 |
| Total Equity | $393.97M | -$276.08M | -$252.58M | -$231.67M | -$231.67M |
| Payables | $5.09M | $3.57M | $4.46M | $5.02M | $5.02M |
| Total Current Liabilities | $13.96M | $51.58M | $14.49M | $18.45M | $18.45M |
| Total Liabilities | $14.48M | $340.84M | $303.16M | $307.19M | $307.19M |
| Total Current Assets | $406.44M | $59.20M | $46.84M | $73.83M | $73.83M |
| Cash and Cash Equivalents & Short-Term Investments | $401.24M | $55.00M | $42.18M | $69.44M | $69.44M |
| -Cash and Cash Equivalents | $401.24M | $55.00M | $42.18M | $69.44M | $69.44M |
| Prepaid Assets | $5.03M | $4.00M | $4.47M | $4.20M | $4.20M |
| Restricted Cash | $168,000.00 | $194,000.00 | $192,000.00 | $192,000.00 | $192,000.00 |
| Total Non-Current Assets | $2.01M | $5.56M | $3.74M | $1.69M | $1.69M |
| Net PPE | $1.58M | $1.76M | $900,000.00 | $1.07M | $1.07M |
| -Gross PPE | $2.59M | $2.71M | $1.80M | $1.93M | $1.93M |
| -Accumulated Depreciation | -$1.01M | -$953,000.00 | -$901,000.00 | -$854,000.00 | -$854,000.00 |
| Other Non-Current Assets | $433,000.00 | $3.80M | $2.84M | $616,000.00 | $616,000.00 |
| Stockholders' Equity | $393.97M | -$276.08M | -$252.58M | -$231.67M | -$231.67M |
| Capital Stock | $7,000.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Common Stock | $7,000.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $706.81M | $15.81M | $13.51M | $11.46M | $11.46M |
| Retained Earnings | -$312.84M | -$291.89M | -$266.09M | -$243.13M | -$243.13M |
| Other Current Liabilities | – | $5.15M | – | – | – |
| -Current Debt | – | $29.90M | – | – | – |
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Special Income (Charges) | -$4.58M | – | – | – | – |
| Gain on Sale of Security | $5.15M | – | – | – | – |
| Other Income (Expense) | $553,000.00 | -$2,000.00 | $1,000.00 | -$1.72M | -$2,000.00 |
| Non-Operating Interest Expense | $699,000.00 | $251,000.00 | – | – | – |
| Non-Operating Interest Income | $2.13M | $264,000.00 | $474,000.00 | $2.94M | $830,000.00 |
| Net Non-Operating Interest Income (Expense) | $1.43M | $13,000.00 | $474,000.00 | $2.94M | $830,000.00 |
| Operating Profit | -$22.93M | -$25.81M | -$23.44M | -$110.39M | -$38.41M |
| Research & Development | $17.50M | $21.23M | $17.63M | $99.53M | $35.82M |
| -General & Admin Expense | $5.43M | $4.58M | $5.80M | $10.86M | $2.59M |
| Operating Expense | $22.93M | $25.81M | $23.44M | $110.39M | $38.41M |
| -Less:Other Special Charges | $4.58M | – | – | – | – |
| Other Non-Operating Income (Expenses) | -$14,000.00 | -$2,000.00 | $1,000.00 | -$1.72M | -$2,000.00 |
| Pretax Profit | -$20.95M | -$25.80M | -$22.96M | -$109.17M | -$37.58M |
| Diluted EPS | -$0.55 | -$0.43 | -$0.52 | -$2.48 | -$0.62 |
| Basic EPS | -$0.55 | -$0.43 | -$0.52 | -$2.48 | -$0.62 |
| Net Income to Common Stockholders | -$20.95M | -$25.80M | -$22.96M | -$109.17M | -$37.58M |
| Net Income to Parent Company | -$20.95M | -$25.80M | -$22.96M | -$109.17M | -$37.58M |
| Profit from Continuing Operations | -$20.95M | -$25.80M | -$22.96M | -$109.17M | -$37.58M |
| Net Profit | -$20.95M | -$25.80M | -$22.96M | -$109.17M | -$37.58M |
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling and Admin Expenses | $5.43M | $4.58M | $5.80M | $10.86M | $2.59M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL |
|---|---|---|---|---|---|
| Operating Cash Flow | -$19.52M | -$21.28M | -$27.07M | -$34.93M | -$97.56M |
| Beginning Cash Balance | $55.21M | $42.42M | $69.72M | $104.64M | $17.92M |
| Net PPE Purchase and Sale | -$36,000.00 | -$110,000.00 | $0.00 | -$1,000.00 | -$136,000.00 |
| Financing Cash Flow | $365.76M | $34.18M | -$230,000.00 | $9,000.00 | $149.50M |
| Net Cash Flow from Continuing Financing Activities | $365.76M | $34.18M | -$230,000.00 | $9,000.00 | $149.50M |
| Net Issuance Payments Of Debt | -$168,000.00 | – | – | – | – |
| Net Preferred Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $149.38M |
| Proceeds from Stock Option Exercised | $265,000.00 | $153,000.00 | $78,000.00 | $9,000.00 | $117,000.00 |
| Ending Cash Balance | $401.41M | $55.21M | $42.42M | $69.72M | $69.72M |
| Net Change in Cash | $346.20M | $12.79M | -$27.30M | -$34.92M | $51.80M |
| Net Cash Flow from Continuing Investing Activities | -$36,000.00 | -$110,000.00 | $0.00 | -$1,000.00 | -$136,000.00 |
| Free Cash Flow | -$19.56M | -$21.39M | -$27.07M | -$34.93M | -$97.69M |
| Net cash flow from continuing operations | -$19.52M | -$21.28M | -$27.07M | -$34.93M | -$97.56M |
| Net cash flow from investing | -$36,000.00 | -$110,000.00 | $0.00 | -$1,000.00 | -$136,000.00 |
| Net Income from Continuing Operations | -$20.95M | -$25.80M | -$22.96M | -$37.58M | -$109.17M |
| Depreciation & Depletion & Amortization | $53,000.00 | $52,000.00 | $47,000.00 | $49,000.00 | $249,000.00 |
| Change in Working Capital | -$1.46M | $1.89M | -$6.26M | $739,000.00 | $2.52M |
| -Change in Prepaid Assets | -$1.03M | $472,000.00 | -$274,000.00 | $796,000.00 | -$979,000.00 |
| Other Non-Cash Items | $861,000.00 | $432,000.00 | $124,000.00 | $121,000.00 | $444,000.00 |
| -Change in Other Current Liabilities | -$165,000.00 | -$160,000.00 | -$136,000.00 | -$132,000.00 | -$446,000.00 |
| -Change in Other Current Assets | $3.35M | -$1.00M | -$2.26M | -$500,000.00 | -$234,000.00 |
| -Change in Payables and Accrued Expense | -$3.62M | $2.58M | -$3.59M | $575,000.00 | $4.18M |
| Net Other Financing Charges | – | -$974,000.00 | -$308,000.00 | – | – |
| Net Common Stock Issuance | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on LTGO.
Sign in to join the discussion.